Literature DB >> 29188268

Sensitivity of Preference-Based Quality-of-Life Measures for Economic Evaluations in Early-Stage Melanoma.

Mbathio Dieng1,2, Nadine A Kasparian3, Anne E Cust2,4, Daniel S J Costa5,6, Anh Tran1, Phyllis N Butow7, Scott W Menzies8,9, Graham J Mann4,10, Rachael L Morton1.   

Abstract

Importance: The diagnosis of a life-threatening disease like melanoma can affect all aspects of a person's life, including health-related quality of life (HRQOL) and psychological aspects of melanoma such as fear of cancer recurrence (FCR). Economic evaluations of psychological interventions require preference-based (utility) instruments that are sensitive to changes in well-being and HRQOL; however, very few studies have evaluated the sensitivity of these instruments when used for people with melanoma. Objective: To compare utility scores from the multiple-attribute instrument Assessment of Quality of Life-8-Dimension Scale (AQoL-8D) with the mapped utility scores of the Functional Assessment of Cancer Therapy-Melanoma (FACT-M) and to investigate the sensitivity of both instruments in identifying the influence of FCR on HRQOL. Design, Setting, and Participants: This assessment of data from a randomized clinical trial of a psychoeducational intervention to reduce FCR, conducted at 3 high-risk melanoma clinics in Australia, evaluated 164 patients with early-stage melanoma and a high risk of developing a second primary melanoma. Main Outcomes and Measures: The FACT-M and AQoL-8D were used to assess HRQOL and FCR among the study participants. Concurrent validity was assessed by comparing the total and subdomain scores of the 2 instruments, and the strength of associations was assessed using Pearson correlation coefficient. Convergent validity was assessed by comparing participants' HRQOL, demographic, and clinical characteristics using the χ2 test and F statistic. Both the FACT-M and AQoL-8D utilities were regressed on FCR Inventory (FCRI) severity scores to estimate the effect of elevated FCR on HRQOL.
Results: A total of 164 participants completed the baseline questionnaires, but only 163 met all inclusion criteria and underwent the full analysis: 72 were women; 91 were men; and mean (SD) age was 58.2 (12.1) years. Both the AQoL-8D and FACT-M instruments showed good concurrent validity and could differentiate between relevant subgroups including level of FCRI severity. The AQoL-8D and FACT-M utilities were strongly correlated (r2 = 0.57). Respondents had a mean (SD) AQoL-8D utility of 0.77 (0.2), and a mean (SD) FACT-M utility score of 0.76 (0.07). High levels of FCRI severity were associated with a decrease in utility of 0.12 (95% CI, -0.19 to -0.05) as measured by AQoL-8D, and a decrease of 0.03 (95% CI, -0.05 to -0.01) as measured by the FACT-M. Conclusions and Relevance: For economic evaluations of psychological interventions in melanoma, the AQoL-8D and FACT-M are valid measures of utility; however, the AQoL-8D demonstrates greater sensitivity to FCRI severity. Our results suggest a significant association between FCR and HRQOL.

Entities:  

Mesh:

Year:  2018        PMID: 29188268      PMCID: PMC5833574          DOI: 10.1001/jamadermatol.2017.4701

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  29 in total

1.  Measuring quality of life: Using quality of life measures in the clinical setting.

Authors:  I J Higginson; A J Carr
Journal:  BMJ       Date:  2001-05-26

2.  Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients.

Authors:  Sharon B Chang; Robert L Askew; Yan Xing; Storm Weaver; Jeffrey E Gershenwald; Jeffrey E Lee; Richard Royal; Anthony Lucci; Merrick I Ross; Janice N Cormier
Journal:  Ann Surg Oncol       Date:  2010-03-25       Impact factor: 5.344

3.  Psychosocial aspects of melanoma.

Authors:  M Gibertini; D S Reintgen; W F Baile
Journal:  Ann Plast Surg       Date:  1992-01       Impact factor: 1.539

4.  A power primer.

Authors:  J Cohen
Journal:  Psychol Bull       Date:  1992-07       Impact factor: 17.737

5.  Survivors of breast cancer: illness uncertainty, positive reappraisal, and emotional distress.

Authors:  M E Mast
Journal:  Oncol Nurs Forum       Date:  1998-04       Impact factor: 2.172

Review 6.  Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies.

Authors:  Sébastien Simard; Belinda Thewes; Gerry Humphris; Mélanie Dixon; Ceara Hayden; Shab Mireskandari; Gozde Ozakinci
Journal:  J Cancer Surviv       Date:  2013-03-10       Impact factor: 4.442

7.  Current state and future prospects of research on fear of cancer recurrence.

Authors:  Sophie Lebel; Gozde Ozakinci; Gerald Humphris; Belinda Thewes; Judith Prins; Andreas Dinkel; Phyllis Butow
Journal:  Psychooncology       Date:  2016-02-18       Impact factor: 3.894

Review 8.  Psychological responses and coping strategies among patients with malignant melanoma: a systematic review of the literature.

Authors:  Nadine A Kasparian; Jordana K McLoone; Phyllis N Butow
Journal:  Arch Dermatol       Date:  2009-12

9.  Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer.

Authors:  Donna Rowen; Tracey Young; John Brazier; Sabine Gaugris
Journal:  Value Health       Date:  2012-12       Impact factor: 5.725

10.  Comparison of the quality of life of early and advanced stage ovarian cancer survivors.

Authors:  Kristina L Mirabeau-Beale; Alice B Kornblith; Richard T Penson; Hang Lee; Annekathryn Goodman; Susana M Campos; Linda Duska; Lauren Pereira; Jessica Bryan; Ursula A Matulonis
Journal:  Gynecol Oncol       Date:  2009-05-28       Impact factor: 5.482

View more
  3 in total

Review 1.  Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma.

Authors:  Francesca Aroldi; Mark R Middleton
Journal:  Am J Clin Dermatol       Date:  2022-03-31       Impact factor: 7.403

Review 2.  Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors.

Authors:  Anne Rogiers; Annelies Boekhout; Julia K Schwarze; Gil Awada; Christian U Blank; Bart Neyns
Journal:  J Oncol       Date:  2019-04-28       Impact factor: 4.375

3.  Protocol for the implementation of a stepped-care model to address fear of cancer recurrence in patients previously diagnosed with early-stage (0-II) melanoma.

Authors:  Jake R Thompson; Andrea L Smith; Serigne N Lo; Nadine A Kasparian; Robyn Pm Saw; Mbathio Dieng; Linda Seaman; Linda K Martin; Pascale Guitera; Donna Milne; Helen Schmid; Anne E Cust; Iris Bartula
Journal:  BMJ Open       Date:  2022-03-03       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.